Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

In-process research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ:OCGN) for for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 8, 2020 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 10, 2024.

OCGN DEADLINE ACTION REMINDER: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Ocugen securities between May 8, 2020 and April 1, 2024, inclusive (the "Class Period").

MMINENT OCGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Ocugen, Inc. Investors to Join the Class Action Lawsuit!

NEW YORK , June 3, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, both dates inclusive (the "Class Period"), of the important June 10, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Ocugen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

OCGN DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm - OCGN

ATLANTA, June 03, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN). The lawsuit alleges that Defendants made materially false and misleading statements and/or failed to disclose material adverse information regarding the Company's business, operations, and prospects, including allegations that: (1) Ocugen's financial statements from May 8, 2020 to the present were materially misstated; and (2) Ocugen did not have adequate internal controls.

Holzer & Holzer, LLC Reminds Shareholders of June 10, 2024 Lead Plaintiff Deadline in Ocugen, Inc. (OCGN) Class Action – Investors With Losses In Excess of $50,000 Encouraged to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ:OCGN) for for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 8, 2020 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 10, 2024.

OCGN DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ:OCGN) for for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 8, 2020 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 10, 2024.

IMPORTANT DEADLINE UPDATE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ:OCGN) for for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 8, 2020 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 10, 2024.

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

MALVERN, Pa., May 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced a positive outcome of the Data and Safety Monitoring Board (DSMB) Review for its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV5-hRORA)—a modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (dAMD). GA affects approximately 2-3 million people in the U.S. and Europe combined.

Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy

LOS ANGELES, CA / ACCESSWIRE / May 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ:OCGN) for for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 8, 2020 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 10, 2024.

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

Ocugen (NASDAQ: OCGN) stock price is doing well this year as investors focus on its ongoing drug trials and its milestones. It has soared by over 177% this year, outperforming the S&P 500, Nasdaq 100, and the iShars Biotechnology ETF (IBB), which has dropped by 2.70%.

Ocugen stock price analysis: good progress but a risky pattern forms

MALVERN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at the 2024 BIO International Convention taking place in San Diego, CA from June 3 – 6, 2024.

Ocugen to Present at BIO International Convention 2024

MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024.

Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Ocugen, Inc. (OCGN) Investors.

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Ocugen, Inc. (OCGN) Investors

NEW YORK , May 24, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, both dates inclusive (the "Class Period"), of the important June 10, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Ocugen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN

LOS ANGELES , May 24, 2024 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) for for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 8, 2020 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 10, 2024.

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses In Excess of $250,000 to Contact the Firm

Ocugen is inching closer towards an approval with (alleged) blockbuster potential. The rest of the company's pipeline looks reasonably deep for its size.

1 Stock That More Than Doubled This Year That I Wouldn't Touch With a 10-Foot Pole

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN) securities between May 8, 2020 and April 1, 2024, inclusive (the “Class Period”). Ocugen investors have until June 10, 2024 to file a lead plaintiff motion. If you suffered a loss on your Ocugen investments or wo.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Ocugen, Inc. (OCGN) Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN) securities between May 8, 2020 and April 1, 2024, inclusive (the “Class Period”). Ocugen investors have until June 10, 2024 to file a lead plaintiff motion. Investors suffering losses on their Ocugen investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Ocugen, Inc. (OCGN) Investors

MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research & Development, Ocugen will speak at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting being held May 29-June 1, 2024 in Vancouver, Canada.

Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024

LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ:OCGN) for for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 8, 2020 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 10, 2024.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ:OCGN) for for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 8, 2020 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 10, 2024.

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

NEW YORK , May 17, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, both dates inclusive (the "Class Period"), of the important June 10, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Ocugen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN

LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ:OCGN) for for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 8, 2020 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 10, 2024.

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ:OCGN) for for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 8, 2020 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 10, 2024.

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses In Excess of $250,000 to Contact the Firm

MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the second cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment for life.

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

News for Ocugen, Inc. Stock (OCGN)